Company Overview - EDAP TMS SA is a global leader in robotic energy-based therapies, focusing on minimally invasive medical devices utilizing ultrasound technology [3] - The company has introduced the Focal One platform, which is recognized as the leading prostate focal therapy controlled by urologists, with potential applications beyond prostate cancer [3] Leadership Appointment - Joshua H. Levine has been appointed to the Board of Directors of EDAP TMS, bringing extensive executive experience in the medical technology sector [1] - Levine's previous roles include President and CEO of Accuray Incorporated, where he led a turnaround that restored consistent growth and profitability [1][2] - He has also served as President and CEO of Immucor, Inc., overseeing its transition to a private entity in a $2 billion acquisition [1][2] Strategic Vision - Levine's appointment is expected to enhance EDAP's strategic vision and execution as the company expands its leadership in advanced HIFU technology applications [1] - The Focal One platform is noted for transforming treatment paradigms in prostate cancer and has potential applications in other therapeutic areas such as endometriosis and BPH [1] Market Position - EDAP TMS has made significant progress in establishing the Focal One platform as the dominant technology for robotic HIFU over the past two years [1] - The company aims to leverage Levine's expertise in portfolio transformation and strategic business development to drive shareholder value [1][2]
EDAP Appoints Joshua H. Levine to Board of Directors